Your browser doesn't support javascript.
loading
Urine transferrin as an early endothelial dysfunction marker in type 2 diabetic patients without nephropathy: a case control study.
Sánchez-Hidalgo, José Juan; Suárez-Cuenca, Juan Antonio; Lozano-Nuevo, José Juan; García-López, Víctor Hugo; Leal-Gutiérrez, María Graciela; León-Angel, Sein Antonio; Ramírez-Villa, María Leslye; Rodea-Rubio, Martha Elena; González-Hernández, José Enrique; Canela-Mayoral, José Antonio; Murillo-Heredia, Eduardo; Vera-Gómez, Eduardo; Hernández-Patricio, Alejandro; Zamora-Alemán, Carlos Ramiro; Domínguez-Pérez, Gabriela Alexandra; Gutiérrez-Buendia, Juan Ariel; Mondragón-Terán, Paul.
Afiliação
  • Sánchez-Hidalgo JJ; Internal Medicine Department, Ticomán General Hospital, Mexico City Health Department. 7, Plan de San Luis, La Purísima Ticomán, Alcaldía Gustavo A. Madero, P.O. 07330, Mexico City, Mexico.
  • Suárez-Cuenca JA; Division of Clinical Research, "20 de Noviembre" National Medical Centre, ISSSTE, No. 540, Félix Cuevas, Colonia del Valle Sur, Alcaldía Benito Juárez, P.O. 03229, Mexico City, Mexico. suarej05@gmail.com.
  • Lozano-Nuevo JJ; Internal Medicine Department, Hospital General de Zona 32. Calzada del Hueso s/n, Coapa, Santa Úrsula Coapa, Alcaldía Coyoacán, P.O. 04980, Mexico City, Mexico. suarej05@gmail.com.
  • García-López VH; Internal Medicine Department, Ticomán General Hospital, Mexico City Health Department. 7, Plan de San Luis, La Purísima Ticomán, Alcaldía Gustavo A. Madero, P.O. 07330, Mexico City, Mexico.
  • Leal-Gutiérrez MG; Internal Medicine Department, Tláhuac General Hospital, Mexico City Health Department, No. 655, Avenida la Turba, Villa Centroamericana I, Alcaldía Tláhuac, P.O. 13250, Mexico City, Mexico.
  • León-Angel SA; National Institute of Medical Sciences and Nutrition "Salvador Zubirán", National Health Institutes, No. 15, Vasco de Quiroga, Belisario Domínguez Sección 16, Alcaldía Tlalpan, P.O. 14080, Mexico City, Mexico.
  • Ramírez-Villa ML; Internal Medicine Department, Ticomán General Hospital, Mexico City Health Department. 7, Plan de San Luis, La Purísima Ticomán, Alcaldía Gustavo A. Madero, P.O. 07330, Mexico City, Mexico.
  • Rodea-Rubio ME; Internal Medicine Department, Ticomán General Hospital, Mexico City Health Department. 7, Plan de San Luis, La Purísima Ticomán, Alcaldía Gustavo A. Madero, P.O. 07330, Mexico City, Mexico.
  • González-Hernández JE; Internal Medicine Department, Xoco General Hospital. Mexico City Health Department. Avenida México Coyoacán S/N, General Anaya, Alcaldía Benito Juárez, P.O. 03340, Mexico City, Mexico.
  • Canela-Mayoral JA; Specialized Clinic for the Management of the Diabetic Patient "Dr. Manuel González Rivera". Calle Manuel Carpio y Calle Salvador Díaz Mirón, Plan de San Luis, Santo Tomas, Alcaldía Miguel Hidalgo, P.O. 11340, Mexico City, Mexico.
  • Murillo-Heredia E; Specialized Clinic for the Management of the Diabetic Patient "Dr. Manuel González Rivera". Calle Manuel Carpio y Calle Salvador Díaz Mirón, Plan de San Luis, Santo Tomas, Alcaldía Miguel Hidalgo, P.O. 11340, Mexico City, Mexico.
  • Vera-Gómez E; Specialized Clinic for the Management of the Diabetic Patient "Dr. Manuel González Rivera". Calle Manuel Carpio y Calle Salvador Díaz Mirón, Plan de San Luis, Santo Tomas, Alcaldía Miguel Hidalgo, P.O. 11340, Mexico City, Mexico.
  • Hernández-Patricio A; Division of Clinical Research, "20 de Noviembre" National Medical Centre, ISSSTE, No. 540, Félix Cuevas, Colonia del Valle Sur, Alcaldía Benito Juárez, P.O. 03229, Mexico City, Mexico.
  • Zamora-Alemán CR; Internal Medicine Department, Hospital General de Zona 32. Calzada del Hueso s/n, Coapa, Santa Úrsula Coapa, Alcaldía Coyoacán, P.O. 04980, Mexico City, Mexico.
  • Domínguez-Pérez GA; Division of Clinical Research, "20 de Noviembre" National Medical Centre, ISSSTE, No. 540, Félix Cuevas, Colonia del Valle Sur, Alcaldía Benito Juárez, P.O. 03229, Mexico City, Mexico.
  • Gutiérrez-Buendia JA; Internal Medicine Department, Hospital General de Zona 32. Calzada del Hueso s/n, Coapa, Santa Úrsula Coapa, Alcaldía Coyoacán, P.O. 04980, Mexico City, Mexico.
  • Mondragón-Terán P; Division of Clinical Research, "20 de Noviembre" National Medical Centre, ISSSTE, No. 540, Félix Cuevas, Colonia del Valle Sur, Alcaldía Benito Juárez, P.O. 03229, Mexico City, Mexico.
Diabetol Metab Syndr ; 13(1): 128, 2021 Nov 07.
Article em En | MEDLINE | ID: mdl-34743740
BACKGROUND: Albumin, along with other proteins, is abnormally eliminated via the urine during early stages of diabetic nephropathy. Moreover, endothelial dysfunction (ED) accompanying early diabetic nephropathy may develop even before microalbuminuria is detectable. Transferrin has a molecular weight comparable to albumin, whereas transferrinuria and microalbuminuria in a 24-h urine sample may comparably reflect early diabetic nephropathy. Whereas transferrin metabolism is related with ED during very early diabetic nephropathy has not been elucidated yet. This case-control study aimed to evaluate the relation between ED and urine transferrin, even before early diabetic nephropathy is present. METHODS: Patients were enrolled from two study sites in Mexico City: Ticomán General Hospital (healthy controls); and a Specialized Clinic for the Management of the Diabetic Patient (cases). All patients provided written informed consent. The primary endpoint was the correlation between urinary transferrin concentration and ED measured in type 2 diabetic patients without albuminuria. ED was evaluated by ultrasonographic validated measurements, which included carotid intima-media thickness (CIMT) and flow mediated dilation (FMD). Plasma biomarkers included glycated hemoglobin, creatinine, cholesterol and triglycerides, as well as urine albumin, transferrin and evidence of urinary tract infection. RESULTS: Sixty patients with type 2 Diabetes Mellitus (t2DM; n = 30) or without t2DM (n = 30), both negative for microalbuminuria, were recruited. The group with t2DM were older, with higher values of HbA1c and higher ED. This group also showed significant differences in urine transferrin and urine/plasma transferrin ratio, as compared with healthy controls (14.4 vs. 18.7 mg/mL, p = 0.04, and 74.2 vs. 49.5; p = 0.01; respectively). Moreover, urine transferrin correlated with higher CIMT values (r = 0.37, p = 0.04), being particularly significant for t2DM population. CIMT also correlated with time from t2DM diagnosis (r = 0.48, p < 0.001) and HbA1c (r = 0.48; p < 0.001). CONCLUSION: Urine transferrin correlated with subclinical atherogenesis in patients with t2DM without renal failure, suggesting its potential to identify cardiovascular risk in patients at very early nephropathy stage without microalbuminuria.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: México

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: México